In summary abiraterone and enzalutamide remain but radium-223 will no longer be available on the NHS – although those currently on treatment will continue. Follow this link to the Prostate Cancer UK news page.
"The first round of delisting saw prostate cancer drug cabazitaxel removed from the CDF in January, but thankfully it has since been placed back on the list and is again available to the men who need it via the CDF."